Clinical Trial Results:
Multinational, Randomized, Double Blind, Double Dummy, Comparative Study to Evaluate the Efficacy and Safety of Telithromycin Oral Suspension, 25 mg/kg Once Daily for 5 Days, Versus Penicillin V Oral Solution, 13.3 mg/kg Three Times Daily for 10 Days, in Children 6 Months to Less Than 13 Years of Age with Streptococcus Pyogenes Tonsillitis/Pharyngitis
Summary
|
|
EudraCT number |
2014-004630-26 |
Trial protocol |
Outside EU/EEA |
Global end of trial date |
20 Sep 2007
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
01 Apr 2016
|
First version publication date |
28 Jun 2015
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
EFC6133, HMR3647B/3004
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT00315042 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Sanofi U.S Services Inc.
|
||
Sponsor organisation address |
55 Corporate Drive Bridgewater, New Jersey, United States, 08807
|
||
Public contact |
Trial Transparency Team, Sanofi aventis recherche & développement
, Contact-US@sanofi.com
|
||
Scientific contact |
Trial Transparency Team, Sanofi aventis recherche & développement
, Contact-US@sanofi.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
27 May 2008
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
20 Sep 2007
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
Primary objective of this study was to compare the bacteriologic efficacy of 5 days of telithromycin to 10 days of penicillin V in subjects with baseline bacterial throat culture positive for Streptococcus pyogenes (S. pyogenes) and repeat throat culture performed at the posttherapy/test-of-cure visit (Visit 3, Days 13 to 17) (per-protocol population for bacteriologic outcome [PPb]).
|
||
Protection of trial subjects |
The study was conducted by investigators experienced in the treatment of pediatric subjects. The parent(s) or guardian(s) as well as the children were fully informed of all pertinent aspects of the clinical trial as well as the possibility to discontinue at any time. In addition to the consent form for the parent(s)/guardian(s), an assent form in child-appropriate language was provided and explained to the child. Repeated invasive procedures were minimized. The number of blood samples as well as the amount of blood drawn were adjusted according to age and weight. A topical anesthesia may have been used to minimize distress and discomfort.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
12 Mar 2006
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United States: 314
|
||
Worldwide total number of subjects |
314
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
2
|
||
Infants and toddlers (28 days-23 months) |
7
|
||
Children (2-11 years) |
289
|
||
Adolescents (12-17 years) |
16
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||||||||||||||
Recruitment details |
The study was conducted at 43 sites in the United States of America. A total of 314 subjects were randomized between 12 March 2006 and 8 June 2006. | |||||||||||||||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||||||||||||||
Screening details |
Of 314 randomized subjects, 305 subjects were treated. | |||||||||||||||||||||||||||||||||
Period 1
|
||||||||||||||||||||||||||||||||||
Period 1 title |
Overall Study (overall period)
|
|||||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||||||||||||||
Blinding used |
Double blind | |||||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator | |||||||||||||||||||||||||||||||||
Arms
|
||||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||||||||||||||
Arm title
|
Telithromycin | |||||||||||||||||||||||||||||||||
Arm description |
Telithromycin for 5 days. | |||||||||||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Telithromycin
|
|||||||||||||||||||||||||||||||||
Investigational medicinal product code |
HMR3647B
|
|||||||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder for oral suspension
|
|||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||||||||||
Dosage and administration details |
25 mg/kg once daily.
|
|||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo (for Penicillin V)
|
|||||||||||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder for oral solution
|
|||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||||||||||
Dosage and administration details |
Placebo matched to penicillin V, 3 times daily for 10 day.
|
|||||||||||||||||||||||||||||||||
Arm title
|
Penicillin V | |||||||||||||||||||||||||||||||||
Arm description |
Penicillin V for 10 days. | |||||||||||||||||||||||||||||||||
Arm type |
Active comparator | |||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Penicillin V Potassium
|
|||||||||||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder for oral solution
|
|||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||||||||||
Dosage and administration details |
13.3 mg/kg 3 times daily.
|
|||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo (for Telithromycin)
|
|||||||||||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder for oral suspension
|
|||||||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
|||||||||||||||||||||||||||||||||
Dosage and administration details |
Placebo matched to telithromycin once daily for 5 days.
|
|||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Telithromycin
|
||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Telithromycin for 5 days. | ||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Penicillin V
|
||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Penicillin V for 10 days. | ||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Telithromycin
|
||
Reporting group description |
Telithromycin for 5 days. | ||
Reporting group title |
Penicillin V
|
||
Reporting group description |
Penicillin V for 10 days. |
|
|||||||||||||||||||
End point title |
Percentage of Subjects According to Bacteriological Outcome in Bacteriological Per Protocol (PPb) Population [1] | ||||||||||||||||||
End point description |
Bacteriologic cure was defined as eradication of S. pyogenes at postbaseline culture (documented eradication). Bacteriologic failure was defined to occur if after 72 hours of study medication, a subject had a positive repeat postbaseline throat culture for S. pyogenes. The PPb population was defined as the per protocol population for analysis of bacteriologic outcome. The PPb population contained all subjects of the clinical per-protocol population (PPc) population with isolation of S. pyogenes at Visit 1 and a postbaseline culture at the Visit 3 and/or Visit 4 time window excluding the major protocol violations. Bacteriologic outcome assessment was made for the visit window in which the culture was obtained.
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
At posttherapy (Day 13-17)
|
||||||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: This study was terminated early (randomization of 314 subjects/760 planned) the type II error was not controlled as planned and only descriptive statistics were generated. |
|||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Percentage of Subjects According to Bacteriological Outcome in Bacteriologic Modified Intent-to-Treat (bmITT) Population | |||||||||||||||||||||
End point description |
Analysis was carried out on bmITT population defined as the bacteriologic modified intent to treat population that included all subjects that were in the modified intent-to-treat (mITT) population with isolation of S. pyogenes at Visit 1.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
At posttherapy (Day 13-17)
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Percentage of Subjects According to Bacteriological Outcome in PPb Population in Late Posttherapy | ||||||||||||||||||
End point description |
Bacteriologic cure was defined as eradication of S. pyogenes at postbaseline culture (documented eradication).Bacteriologic failure was defined to occur if after 72 hours of study medication, a subject had a positive repeat postbaseline throat culture for S. pyogenes. Analysis was performed on PPb population. Number of subjects analysed = subjects with data available at Day 38-45.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
At late posttherapy (Day 38-45)
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Number of Subjects with Adverse Events of Special Interest | ||||||||||||||||||
End point description |
Analysis was carried out on safety population which included all randomized and treated subjects.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
7 days after end of treatment
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Day 38-45) regardless of seriousness or relationship to investigational product. Analysis was performed on safety population.
|
||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Reported adverse events are treatment-emergent adverse events that is AEs that developed/worsened during the ‘on treatment period’ (first dose of study medication and up to 7 days after the last dose of study medication or, up to 17 days after the first dose of study medication, whichever is later).
|
||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||
Dictionary version |
10.1
|
||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||
Reporting group title |
Telithromycin
|
||||||||||||||||||||||||||||||
Reporting group description |
Telithromycin for 5 days. | ||||||||||||||||||||||||||||||
Reporting group title |
Penicillin V
|
||||||||||||||||||||||||||||||
Reporting group description |
Penicillin V for 10 days. | ||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||
|
|
|||||||
Substantial protocol amendments (globally) |
|||||||
Were there any global substantial amendments to the protocol? No | |||||||
Interruptions (globally) |
|||||||
Were there any global interruptions to the trial? Yes | |||||||
|
|||||||
Limitations and caveats |
|||||||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||||||
None reported |